BioLineRx Ltd. BLRX
2.60
0.08
3.17%
as of 25 Sep
- Market cap
- $12.6M
- P/E
- 0.0×
Follow BLRX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
P/S ratio |
9.65 | 0.58 | 0.00 | — | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
P/Operating CF |
(3.56) | (1.95) | 19.69 | — | — | — | — | — | — | — |
P/B ratio |
0.49 | 1.25 | 7.43 | — | — | — | — | — | — | — |
Price to Tangible BV |
1.63 | 5.57 | 0.00 | — | — | — | — | — | — | — |
EV/Sales |
(0.47) | 0.37 | 0.00 | — | — | — | — | — | — | — |
EV/EBITDA |
0.06 | 0.00 | 0.00 | — | — | — | — | — | — | — |
EV/Operating CF |
0.07 | (0.24) | (2.88) | — | — | — | — | — | — | — |
EV/FCF |
0.07 | (0.24) | (2.84) | — | — | — | — | — | — | — |
Quick Ratio |
1.76 | 1.53 | 1.03 | 4.85 | 5.89 | 2.14 | 2.35 | 4.66 | 7.45 | 9.79 |
Current Ratio |
1.95 | 1.76 | 1.10 | 4.87 | 5.91 | 2.15 | 2.36 | 4.74 | 7.49 | 9.86 |
Net Debt/EBITDA |
1.22 | 0.37 | 0.69 | 1.44 | 2.19 | 0.76 | 0.70 | 0.85 | 1.99 | 2.20 |
Debt/Assets |
21.85% | 34.54% | 15.29% | 13.31% | 5.52% | 12.33% | 15.85% | 15.53% | 0.41% | 0.88% |
Debt/Equity |
0.38 | 1.00 | 0.74 | 0.20 | 0.07 | 0.26 | 0.25 | 0.21 | 0.00 | 0.01 |
Asset Turnover |
0.03 | 0.56 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
6.87 | 4.76 | 0.37 | 1.05 | 0.87 | 0.77 | 0.89 | 1.05 | 0.84 | 0.92 |
Capex/Depreciation |
(0.05) | (0.01) | (0.21) | (0.48) | (0.14) | 0.00 | (0.08) | (18.74) | (8.81) | (0.11) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (6.38%) | (69.11%) | (189.23%) | (41.96%) | (60.04%) | (108.36%) | (68.13%) | (48.75%) | (55.40%) | (38.34%) | |
| (2.94%) | (17.93%) | (86.40%) | (31.63%) | (42.05%) | (59.53%) | (46.35%) | (39.18%) | (48.75%) | (35.11%) | |
ROIC |
(56.36%) | (173.87%) | 0.00% | (183.57%) | (100.28%) | (271.65%) | (122.16%) | (80.41%) | (432.43%) | 0.00% |
Return on Tangible Assets |
(10.03%) | (76.31%) | (1,244.13%) | (59.34%) | (55.62%) | (221.07%) | (140.91%) | (83.64%) | (52.76%) | (45.20%) |
Average Days of Receivables |
141.05 | 49.87 | 90.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
685.85% | 31.61% | 260.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
266.44% | 103.41% | 657.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.40 | 0.27 | 0.23 | 0.29 | 0.27 | 0.46 | 0.41 | 0.39 | 0.12 | 0.00 |
Share Based Compensation of Revenue |
33.56% | 3.92% | 48.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.54 | 0.10 | (0.04) | — | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
Earnings Yield |
(6.14%) | (53.82%) | (61.18%) | — | — | — | — | — | — | — |
Free Cash Flow Yield |
(71.28%) | (262.39%) | (23.31%) | — | — | — | — | — | — | — |
Revenue per Share |
0.29 | 14.49 | 2.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.96) | (21.97) | (14.08) | (20.34) | (21.33) | (55.07) | (92.89) | (133.66) | (136.98) | (155.05) |
Capex per Share |
(0.01) | (0.03) | (0.18) | (0.24) | (0.09) | 0.00 | (0.30) | (56.44) | (28.25) | (0.59) |
Free Cash Flow per Share |
(1.97) | (22.00) | (14.27) | (20.59) | (21.42) | (55.07) | (93.19) | (190.10) | (165.23) | (155.64) |
Cash per Share |
5.08 | 9.80 | 26.78 | 39.60 | 51.71 | 53.60 | 112.66 | 166.58 | 329.89 | 380.59 |
Shareholders Equity per Share |
5.68 | 6.74 | 8.24 | 39.41 | 61.62 | 52.28 | 136.80 | 228.29 | 352.54 | 374.22 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.68 | 6.74 | 8.24 | 39.41 | 61.62 | 52.28 | 136.80 | 228.29 | 352.54 | 374.22 |
Free Cash Flow |
(8.10) | (43.93) | (22.90) | (26.56) | (23.67) | (23.21) | (22.74) | (34.41) | (24.78) | (14.57) |
Working Capital |
11.56 | 11.70 | 4.40 | 41.32 | 47.69 | 12.24 | 16.24 | 25.23 | 43.65 | 32.44 |
Capital Expenditures |
(0.03) | (0.05) | (0.30) | (0.32) | (0.10) | — | (0.07) | (10.22) | (4.24) | (0.05) |
Net Current Asset Value |
6.12 | 1.66 | (3.52) | 26.46 | 44.10 | (2.38) | 8.02 | 17.07 | 42.29 | 32.19 |
EV/EBIT |
0.05 | 0.00 | 0.00 | — | — | — | — | — | — | — |
Capex to Sales |
0.02 | 0.00 | 0.06 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
(99.58%) | (31.86%) | (1,262.79%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
3.27 | 10.53 | 2.93 | 0.90 | 0.74 | 0.70 | 0.52 | 0.24 | 0.19 | 0.19 |
Cash ROIC |
(15.49%) | (95.26%) | (34.98%) | (24.06%) | (18.91%) | (48.66%) | (35.30%) | (32.94%) | (22.46%) | (24.11%) |
Accounts Receivable Turnover |
0.54 | 11.26 | 5.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.03 | 0.81 | 0.32 | 0.08 | 0.10 | 0.12 | 0.13 | 0.07 | 0.10 | 0.15 |
Inventory Turnover |
0.09 | 3.63 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
8,309.30 | 343.37 | 1,406.02 | 5,092.66 | 3,390.26 | 2,683.91 | 3,421.58 | 4,943.20 | 4,852.88 | 2,702.76 |
Days of Inventory on Hand |
3,408.78 | 123.93 | 193.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
2.21 | 2.57 | 0.95 | 0.43 | 0.14 | 0.38 | 0.98 | 0.96 | 0.40 | 0.26 |
Average Payables |
6.98 | 11.47 | 11.47 | 7.75 | 7.08 | 8.22 | 7.47 | 6.24 | 5.10 | 3.31 |
Average Inventory |
2.65 | 2.55 | — | — | — | — | — | — | — | — |
Average Assets |
39.91 | 51.42 | 70.15 | 78.89 | 64.34 | 50.43 | 54.90 | 58.60 | 49.95 | 45.12 |
Average Common Equity |
18.40 | 13.34 | 32.03 | 59.46 | 45.06 | 27.71 | 37.35 | 47.10 | 43.95 | 41.32 |
Columns are period end dates